医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ringing in the New Year With a New Name! Shinkowa Pharmaceutical Co., Ltd., Is Now MIRAILAB BIOSCIENCE Inc.

2021年01月07日 AM01:00
このエントリーをはてなブックマークに追加


 

TOKYO

Since 2016, Shinkowa Pharmaceutical Co., Ltd., has been proud of its work as a bio-venture company, convinced of the infinite possibilities of science, and experiencing the joy of realizing such possibilities in our own laboratories one by one, year by year.

Each year we look back upon, adding to our knowledge and experience, and cherishing each accomplishment, the more we see in our future and the more we are inspired to achieve in years to come. So powerful has this inspiration become, and so close to our hearts, that as of January 1, this year, Shinkowa Pharmaceutical Co., Ltd., has taken a new name:

MIRAILAB BIOSCIENCE Inc.

https://en.mirailab-bio.com/

“Mirai” means “future” in Japanese. Our new name reflects our ever-increasing feeling of hope for the future, our passion to reach greater goals, and our commitment to realize the new possibilities that emerge from every development and discovery.

We are grateful to all our customers and stakeholders who share in and support us in our new name’s spirit!

MIRAILAB BIOSCIENCE Inc.

Megumi Tanaka, CEO

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005322/en/

CONTACT

Inquiries:

MIRAILAB BIOSCIENCE Inc.

Public Relations

Ayuko Matsuda

E-mail: info@mirailab-bio.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™